Compare Apple Inc (AAPL) vs Illumina, Inc. (ILMN) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Apple Inc vs Illumina, Inc. — how do they compare? Apple Inc trades at $313.86 (market cap $4.56T), while Illumina, Inc. trades at $187.83 (market cap $29.01B). The key difference: Apple Inc is far larger — about 157.2× Illumina, Inc.'s market cap, and Apple Inc pays a 0.35% dividend while Illumina, Inc. pays none. Which is the better fit depends on your goals.
| AAPL | ILMN | |
|---|---|---|
Market Cap | $4.56T | $29.01B |
Volume | 100,358,844 | — |
Sector | Technology | Health |
52-Week High | $315.20 | $194.33 |
52-Week Low | $202.38 | $91.00 |
Enterprise Value | $4.58T | $30.40B |
Dividend Yield | 0.35% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Apple (AAPL) trades at $314.03, up 0.44% today, with a bullish technical signal from moving averages and a consensus analyst price target of $329.62. Recent quarterly earnings have consistently beaten expectations, with Q1 2026 EPS of $2.01 surpassing the $1.95 estimate. Revenue grew to $416.16B in 2025, and net income reached $112.01B. The company maintains strong profitability with a 47.86% gross margin and 27.15% net margin, though valuation ratios like P/E of 37.61 are elevated. A dividend of $0.27 is scheduled for payment on May 14, 2026.
The outlook for AAPL remains positive driven by earnings beats and AI opportunities, but risks include high valuation, competitive pressures, and potential regulatory scrutiny. Institutional sentiment is bullish with 62.73% buy ratings, though technical indicators show mixed signals with RSI suggesting mild overbought conditions near-term.
ILMN trades at $191.76, up 1.63% with bullish technical momentum and strong earnings beats. The stock shows robust profitability with 66.2% gross margins and 19.42% net income margins, though valuations remain elevated with a P/E of 34.31. Recent product launches like StrataMap Spatial and NovaSeq X demand drive growth, while Roche's new Axelios sequencer introduces competitive pressure. Cash flow improved to $291M in 2025 after prior volatility.
Outlook remains positive with analyst consensus at Buy (51%) and a $168.89 price target, though current price exceeds consensus. Key risks include rising debt-to-asset ratios (29.93% in 2025) and China market challenges. Upside depends on execution against new competition and sustaining high-margin sequencing growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Apple Inc
Apple Inc. designs, manufactures, and markets personal computers and related personal computing and mobile communication devices along with a variety of related software, services, peripherals, and networking solutions. Apple sells its products worldwide through its online stores, its retail stores, its direct sales force, third-party wholesalers, and resellers.
Read more on AAPL →About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →
